

# Commercial/Healthcare Exchange PA Criteria Effective: January 1, 2021

**Prior Authorization:** Uceris Rectal Foam

Products Affected: Uceris 2mg rectal foam

<u>Medication Description</u>: Budesonide has glucocorticosteroid (GCS) activity. Glucocorticoids are naturally occurring hormones that prevent or suppress inflammation and immune responses when administered at pharmacological doses. In general, glucocorticoids inhibit the activity of a variety of cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators involved in allergic and nonallergic/irritant-mediated inflammation (e.g., histamine, eicosanoids, leukotrienes, and cytokines).

*Covered Uses:* Indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.

## *Exclusion Criteria*: N/A

### **Required Medical Information:**

- 1. Diagnosis
- 2. Previous therapies tried and failed

Age Restrictions: 18 years of age and older

### Prescriber Restrictions: N/A

### Coverage Duration: 6 months

#### **Other Criteria:**

- A. Patient has a diagnosis of distal ulcerative colitis; AND
- B. Patient has a documented intolerance to, contraindication, or treatment failure with a mesalamine rectal product (e.g. mesalamine 4 G/60 ml rectal enema, or mesalamine 1 G suppository) AND a hydrocortisone rectal product (e.g. hydrocortisone 100 mg / 60 ml rectal enema, hydrocortisone acetate 10% rectal foam, or hydrocortisone 25 mg or 30 mg rectal suppository)

#### **<u>References</u>**:

1. Uceris (budesonide) rectal foam [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; April 2020.

### Policy Revision history

Rev # Type of Change	Summary of Change	Sections Affected	Date	
----------------------	-------------------	-------------------	------	--

January 2021



# ConnectiCare.

1	New Policy	New Policy	All	1/1/2021
---	------------	------------	-----	----------



January 2021